Chimerix Inc
NASDAQ:CMRX

Watchlist Manager
Chimerix Inc Logo
Chimerix Inc
NASDAQ:CMRX
Watchlist
Price: 3.02 USD 1% Market Closed
Market Cap: 271.6m USD
Have any thoughts about
Chimerix Inc?
Write Note

Chimerix Inc
Other Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Chimerix Inc
Other Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Chimerix Inc
NASDAQ:CMRX
Other Liabilities
$644k
CAGR 3-Years
-36%
CAGR 5-Years
10%
CAGR 10-Years
3%
Abbvie Inc
NYSE:ABBV
Other Liabilities
$33B
CAGR 3-Years
4%
CAGR 5-Years
16%
CAGR 10-Years
28%
Gilead Sciences Inc
NASDAQ:GILD
Other Liabilities
$24.4B
CAGR 3-Years
63%
CAGR 5-Years
29%
CAGR 10-Years
39%
Amgen Inc
NASDAQ:AMGN
Other Liabilities
$4.5B
CAGR 3-Years
-20%
CAGR 5-Years
-14%
CAGR 10-Years
-4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Liabilities
$2.5B
CAGR 3-Years
56%
CAGR 5-Years
50%
CAGR 10-Years
44%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Liabilities
$1.8B
CAGR 3-Years
35%
CAGR 5-Years
13%
CAGR 10-Years
23%
No Stocks Found

Chimerix Inc
Glance View

Market Cap
271.6m USD
Industry
Biotechnology

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Durham, North Carolina and currently employs 87 full-time employees. The company went IPO on 2013-04-11. The firm is focused on discovering, developing and commercializing medicines that address unmet medical needs. The firm offers TEMBEXA (brincidofovir) is an antiviral for the treatment of smallpox in all age groups, including infants, and for patients who have difficulty swallowing. The firm's product Imipridones is a cancer therapies, which provides ONC201 for brain and other cancers, ONC206 for central nervous system cancer and ONC212 for pancreatic cancer and leukemia. The Company’s DSTAT is a glycosaminoglycan derivative of heparin, which is a treatment for hematologic malignancies, including newly diagnosed acute myeloid leukemia (AML) in combination with standard chemotherapy.

CMRX Intrinsic Value
2.98 USD
Overvaluation 1%
Intrinsic Value
Price

See Also

What is Chimerix Inc's Other Liabilities?
Other Liabilities
644k USD

Based on the financial report for Sep 30, 2024, Chimerix Inc's Other Liabilities amounts to 644k USD.

What is Chimerix Inc's Other Liabilities growth rate?
Other Liabilities CAGR 10Y
3%

Over the last year, the Other Liabilities growth was -57%. The average annual Other Liabilities growth rates for Chimerix Inc have been -36% over the past three years , 10% over the past five years , and 3% over the past ten years .

Back to Top